"The Biggest Issue in Global Biohealth: 'Medical Cost Inflation'"
Global Healthcare Costs Projected to Rise Around 10%
GLP-1 Drugs, Novel Therapies, and Mental Health Demand Drive Increases
AI Expansion Fails to Ease, and May Even Exacerbate, Cost Pressures
Rising healthcare costs have emerged as a key variable in the global biohealth industry. Despite the proliferation of artificial intelligence (AI) and digital health solutions, the combination of high-priced novel drugs and the increasing prevalence of chronic diseases is shaping the cost burden across the entire industry.
On March 24, the Korea Health Industry Development Institute analyzed 12 industry outlook reports from global consulting firms such as Deloitte, PwC, and KPMG, as well as healthcare specialist organizations, and identified "medical cost inflation" as the most important keyword for this year.
Last year, the global healthcare cost growth rate reached 10.0%, its highest level in 13 years, and major institutions expect this year's growth rate to be close to 10% as well. In its "Medical Cost Trend: Behind the Numbers 2026" report, PwC projected the U.S. healthcare cost growth rate for employer-sponsored plans at 8.5% in 2026. The rate of increase in pharmaceutical spending was found to be about 2.5 percentage points higher than overall healthcare costs. WTW forecast the global healthcare cost growth rate for the same year at 10.3%, while Marsh projected an increase of 11.1%.
The main drivers of medical inflation include high pricing for new drugs and the widespread use of biologics. In particular, the expansion of glucagon-like peptide-1 (GLP-1) drugs for obesity and diabetes treatment, as well as the launch of new drugs for cancer and immune diseases, are fueling cost increases. At the same time, rising demand for mental health services and the growing prevalence of chronic diseases are driving up overall healthcare utilization. PwC stated in its report, "GLP-1 drugs are expected to account for 0.5% to 1.0% of this year's medical cost trend. While GLP-1 drugs significantly improve quality of life and help prevent long-term complications, their requirement for chronic administration can result in sustained cost burdens."
Some analyses suggest that the spread of technology may actually drive costs higher. The expansion of AI-based diagnostics and healthcare service management is improving accuracy and accessibility, but under the fee-for-service system, these productivity gains do not necessarily translate into cost savings. Instead, the increase in precision diagnostics may lead to additional testing and treatments, further raising total healthcare expenditures. In response to rising medical costs, global insurance companies are already considering reducing coverage and increasing out-of-pocket expenses for patients. In South Korea as well, there is a trend toward higher pharmaceutical expenses, but due to government price controls and the national health insurance system, instead of sharp price hikes, the result has been an accumulation of fiscal pressure.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Cost containment strategies include the use of biosimilars and a greater focus on preventive care management. As expensive biopharmaceuticals and new drugs drive medical cost inflation, the strategic value of biosimilars—which are relatively less expensive—is growing. The recent move by the U.S. Food and Drug Administration (FDA) to ease biosimilar development and approval procedures reflects this trend. The Korea Health Industry Development Institute noted, "Last year, the global biohealth industry achieved digital transformation (DX) and AI innovation, but structural challenges such as soaring healthcare costs and widening gaps in access persist. Despite the expansion of the digital health market and AI adoption, disparities in technology between healthcare institutions and countries have become even more pronounced."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.